Management of Dyslipidemia in Patients with Atherosclerotic Disease and Liver Concerns
First-Line Additional Therapy
- The European Society of Cardiology recommends ezetimibe (10 mg daily) as the first-line addition to rosuvastatin for patients with established atherosclerotic disease and liver concerns, providing an additional 15-20% LDL-C reduction 1, 2
Rationale for Ezetimibe Selection
- The European Heart Journal guidelines categorize patients with established atherosclerotic disease, such as atherosclerotic aorta, as very high-risk, requiring aggressive lipid management with a target LDL-C goal of <1.4 mmol/L (55 mg/dL) and at least a 50% reduction from baseline 2
Second-Line Options if LDL-C Goals Not Achieved
- The American College of Cardiology recommends considering bempedoic acid as the next addition if LDL-C goals are not achieved with rosuvastatin plus ezetimibe, as it reduces LDL-C by an additional 15-25% and has shown a 13% reduction in major adverse cardiovascular events in statin-intolerant patients 1, 2
Third-Line Options for Very High-Risk Patients
- The European Heart Journal guidelines suggest adding PCSK9 inhibitors (evolocumab or alirocumab) if LDL-C remains above target despite combination therapy, as they can reduce LDL-C by an additional 60% and demonstrate significant reduction in non-fatal cardiovascular events 1, 2
Special Considerations for Liver Disease
- Regular monitoring of liver function tests is essential when managing dyslipidemia in patients with parenchymal liver disease, according to the American Association for the Study of Liver Diseases 4